Zenas BioPharma Revenue and Competitors

Boston, MA USA

Location

N/A

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • Zenas BioPharma's estimated annual revenue is currently $14.9M per year.(i)
  • Zenas BioPharma's estimated revenue per employee is $121,967

Employee Data

  • Zenas BioPharma has 122 Employees.(i)
  • Zenas BioPharma grew their employee count by 37% last year.

Zenas BioPharma's People

NameTitleEmail/Phone
1
Founder, CEO & ChairmanReveal Email/Phone
2
President and Chief Operating OfficerReveal Email/Phone
3
Chief Human Resources OfficerReveal Email/Phone
4
Head R&D and CMOReveal Email/Phone
5
CBO & CFOReveal Email/Phone
6
Chief Commercial OfficerReveal Email/Phone
7
VP Clinical DevelopmentReveal Email/Phone
8
VP, Head LegalReveal Email/Phone
9
VP, Global Quality AssuranceReveal Email/Phone
10
VP, PharmacovigilanceReveal Email/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$5.2M67-45%$107.3MN/A
#2
$0.3M1-50%N/AN/A
#3
$5.1M3322%N/AN/A
#4
$11.9M77-37%$312.8MN/A
#5
$0.9M2-60%N/AN/A
#6
$235M300-5%$340.9MN/A
#7
$45.9M237-7%$7.6MN/A
#8
$3.9M5035%N/AN/A
#9
N/A1110%N/AN/A
#10
$5.4M290%N/AN/A
Add Company

What Is Zenas BioPharma?

Zenas BioPharma is a global biopharmaceutical company committed to becoming a leader in the development and delivery of immune-based therapies for patients around the world. Zenas is rapidly advancing a deep portfolio of innovative therapeutics that continues to grow through our successful business development strategy. Our experienced leadership team and network of business partners drive operational excellence to deliver potentially transformative therapies to improve the lives of those facing autoimmune and rare diseases. For more information about Zenas BioPharma, please visit www.zenasbio.com.

keywords:N/A

N/A

Total Funding

122

Number of Employees

$14.9M

Revenue (est)

37%

Employee Growth %

N/A

Valuation

N/A

Accelerator

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$16.3M12558%N/A
#2
$40.7M12626%N/A
#3
$41.2M128-6%N/A
#4
$26.9M1288%N/A
#5
$26.3M13112%$134.5M